E. D. de Vries

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

J. Verweij, E. de Vries, J. Gietema, 2007, British Journal of Cancer.

Combination therapy with cisplatin: modulation of activity and tumour sensitivity.

H. Guchelaar, N. Mulder, E. de Vries, 1992, Clinical oncology (Royal College of Radiologists (Great Britain)).

Radiolabeled amino acids: basic aspects and clinical applications in oncology.

W Vaalburg, K. Langen, J. Pruim, 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines.

F. Baas, A. Smith, N. Mulder, 1993, Cancer research.

Feasibility of tumor imaging using L-3-[iodine-123]-iodo-alpha-methyl-tyrosine in extracranial tumors.

H. Groen, E. Franssen, W. Vaalburg, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Enhancement of cisplatin and etoposide cytotoxicity after all‐trans retinoic‐acid‐induced cellular differentiation of a murine embryonal carcinoma cell line

H. Guchelaar, N. Mulder, E. de Vries, 1993, International journal of cancer.

A potential role of macrophage activation in the treatment of cancer.

E. de Vries, G. Scherphof, T. Daemen, 2002, Critical reviews in oncology/hematology.

Alpha-fetoprotein-lectin binding as a marker of tumour activity or liver damage.

E. de Vries, D. Sleijfer, H. Schraffordt koops, 1990, European journal of cancer.

Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma

N. Mulder, E. de Vries, H. de Vries, 2000, Cancer.